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Abstract
Major depressive disorder (MDD) is the most severe form of depression and the leading cause of disability worldwide.
When considering research approaches aimed at understanding MDD, it is important that their effectiveness is evaluated.
Here, we assessed the effectiveness of original studies on MDD by rating their contributions to subsequent medical papers
on the subject, and we compared the respective contribution of findings from non-human primate (NHP) studies and from
human-based in vitro or in silico research approaches. For each publication, we conducted a quantitative citation analysis
and a systematic qualitative analysis of the citations. In the majority of cases, human-based research approaches (both in
silico and in vitro) received more citations in subsequent human research papers than did NHP studies. In addition, the
human-based approaches were considered to be more relevant to the hypotheses and/or to the methods featured in the
citing papers. The results of this study suggest that studies based on in silico and in vitro approaches are taken into account
by medical researchers more often than are NHP-based approaches. In addition, these human-based approaches are
usually cheaper and less ethically contentious than NHP studies. Therefore, we suggest that the traditional animal-based
approach for testing medical hypotheses should be revised, and more opportunities created for further developing
human-relevant innovative techniques.
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Introduction
According to the World Health Organization, depression is
the leading cause of morbidity worldwide. It affects more
than 300 million people of all ages and is a major contri-
butor to the overall global burden of disease.1 People who
suffer from depression are more prone to an early death
either by suicide or through the development of other con-
ditions such as cancer, heart disease or stroke.2,3 In addi-
tion, these patients are also more prone to a number of other
disorders (e.g. osteoporosis)4 that, although not life-
threatening, do significantly impact not only quality of life
but also public health and national economies.
Accordingly, major investment has been dedicated
to research aiming to improve the understanding of all
eight forms of depression.5 Major depressive disorder
(MDD) is the most severe type and the third leading cause
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of long-term disability.6 Besides, the few studies that have
comprehensively investigated the impact of MDD in Eur-
ope (from 2004 to 2010) have shown that MDD was the
costliest brain disorder in Europe, accounting for at least
1% of the total European economy.7,8 In the United States,
the economic burden of MDD alone was US$210.5 billion
in 2010.9
Clinical research is expensive, time-consuming and
potentially ethically contentious. For instance, every
patient who enrols in a clinical trial is subject to an
increased level of risk with respect to deviations from their
regular clinical care, particularly with regard to the occur-
rence of unexpected effects from exposure to a new treat-
ment. Non-clinical (i.e. preclinical) research, often
involving non-human animals and human-based in vitro
and in silico approaches, is sometimes valuable in the early
steps of biomedical research to simplify and accelerate
drug and treatment discovery. However, to optimise the
outcomes of this non-clinical research, it is crucial to eval-
uate the research approaches that might have the most
potential for patient treatment results.
Animal-based research has been accepted as the ‘gold
standard’ approach for preclinical biomedical research and
testing since the second half of the 20th century.10 Within
this approach, non-human primate (NHP) research has been
considered particularly relevant, due to the similarity
between humans and NHPs. However, this similarity has
led to NHPs being afforded various degrees of legal pro-
tection in different regions of the world. For example, Eur-
ope,11 the United States12 and New Zealand13 have
imposed considerable restrictions to the use of NHPs for
scientific purposes. These restrictions are due to the under-
standing that subjecting NHPs to laboratory confinement
alone, even before considering the use of any invasive or
intrusive procedures, has resulted in psychosomatic injury,
mutilation and physiological traits that have been com-
pared to those exhibited by people with post-traumatic
stress disorder.13–20 Moreover, NHPs are expensive to
acquire21 and are the most expensive animals to maintain.22
The legislation on animal use for experimental purposes
of several countries (e.g. Directive 2010/63/EU) requires a
cost–benefit assessment to be carried out prior to conduct-
ing a procedure on a non-human animal. For each project,
the likely harm to the animal should be balanced against the
potential benefits, and the project should only go ahead if
the expected benefits outweigh the harms inflicted to the
animals involved.
Considering all of the above, it is assumed that when
research is conducted on NHPs, due to the ethical and
economic concerns surrounding this practice, this research
should provide highly relevant data that lead to concrete
improvements in patient outcomes. While some authors
assert that animal research approaches, and those involving
NHPs in particular, are crucial for biomedical progress,23
an increasing number of evidence-based papers show that
the contribution of animal-based research to the advance-
ment of human healthcare has been poor,24 including in the
case of MDD.25 However, it is yet to be established
whether this poor contribution is due to the intrinsic limita-
tions of all non-clinical research, or whether human-based
(in vitro and in silico) non-clinical research approaches are
more effective in helping biomedical progress, at least
when seeking to understand complex disorders of a multi-
factorial origin, such as MDD.
In vitro and in silico methods that directly rely on
human-based knowledge and/or material are thought to
potentially allow for faster development of medical treat-
ments.26,27 Usually, they are also more cost-effective than
animal-based methods. However, despite yielding data of
sufficient value to further disease understanding in humans,
and providing the means to test new therapies, such non-
animal methods are still judged against the standard
biomedical research paradigm. Indeed, they are seen as
incomplete on their own and considered to be preliminary
steps prior to (often contradictory) animal testing.28,29
To shed light on this debate, the current study examines
and compares the contribution of results from NHP studies,
as well as from in silico-based and in vitro-based
approaches, to clinical studies on MDD. This allows us
to: (a) evaluate whether the low transferability of knowl-
edge to clinical research is a common trait of all non-
clinical research approaches; and (b) evaluate the specific
relevance of NHP studies and human-based in silico and in
vitro approaches to human clinical studies.
Considering the dominance of NHP studies within the
current preclinical research paradigm, we expect the find-
ings from these studies to have a higher contribution to
subsequent clinical research than findings from in silico-
based and in vitro-based studies. A similar or lower contri-
bution from NHP studies would suggest that clinical
research is becoming less reliant on this more costly and
ethically questionable type of research, thus suggesting that
the time for a paradigm shift has come.
Methods
The design of this study was based on a previously devel-
oped method consisting of a quantitative citation analysis
and a systematic qualitative analysis of citations.30
Quantitative citation analysis
Bibliographic search: The citation analysis was performed
between September 2016 and June 2017. The PubMed bib-
liographic database was searched for papers that described
studies employing either NHPs, or in vitro or in silico
research approaches, to investigate MDD. The following
Medical Subject Heading (MeSH) search terms were used:
‘Depressive Disorder, Major’ ANDMeSH terms: ‘primate’
OR ‘ape’ OR ‘macaque’ OR ‘macaca’ OR ‘rhesus’ OR
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‘chimpanzee’ OR ‘bonobo’ OR ‘gorilla’ OR ‘gorila’ OR
‘Pan’ OR ‘orangutang’ OR ‘orang-utan’ OR ‘Orang utan’
OR ‘orangutan’ OR ‘ourang-outang’ OR ‘Pongo’ OR
‘gibbon’ OR ‘Hylobates’ OR ‘Colobus’ OR ‘Baboon’
OR ‘Papio’ OR ‘Mandrillus’ OR ‘Mandrill’ OR ‘Cebus’
OR ‘Cebuella’ OR ‘Brachyteles’ OR ‘Loris’ OR ‘Nycti-
cebus’ OR ‘lemur’ OR ‘Callithrix’ OR ‘in silico’ OR
‘computer model’ OR ‘mathematical model’ OR ‘com-
puter simulation’ OR ‘in vitro’ OR ‘cell culture’ OR ‘cul-
ture technique’ OR ‘cell line’ OR ‘organ culture’ OR
‘tissue culture’.
MeSH terms are a comprehensive list of key terms
related to each human disorder, designed to identify all
relevant studies in a given area.31 Thus, searching for
‘Depressive Disorder, Major’ retrieves other nomencla-
tures for the same disorder (e.g. Melancholia). There were
no exclusive MeSH terms for NHPs, so the search retrieved
additional papers with non-human animals that were
excluded by manual sorting. All in vitro-based and in
silico-based papers that used animal data (e.g. rat cell line
data) were also excluded.
Papers from scientific journals, books, research reports
and conference proceedings written in English, Portuguese
or Italian were included (being within the authors’ linguistic
fluencies). PubMed filters were used, in order to exclude
review papers (‘review’, ‘systematic review’, ‘meta-analy-
sis’, ‘bibliography’), as well as editorials and other types of
non-research papers (‘biography’, ‘auto-biography’, ‘com-
ment’, ‘opinion paper’, ‘interview’), since the aim of the
study was to evaluate the impact of original data. The search
was restricted to publications prior to 31 December 2011, to
allow adequate time for subsequent citation of papers.32
Nineteen NHP study-based papers, 29 in silico-based papers
and 38 in vitro-based papers describing data from original
MDD research were retrieved (see Appendix 1).
Citation data: A citation analysis on the retrieved papers was
performed by using the cited reference search facility
within the Web of Science bibliographic database. For each
retrieved paper, the subsequent papers that cited it were
identified, and three types of citation data were recorded:
– the total number of times that the retrieved paper
was cited;
– the total number of times that the retrieved paper
was cited per research category; and
– the total number of times that the retrieved paper
was cited per research subject, that is, on MDD or
other subjects, as detailed below.
Each citing paper was ascribed to one or more of the fol-
lowing eight research categories: ‘invasive animal
research’; ‘human research’; ‘review’; ‘opinions’ (includ-
ing editorials, comments or replies to comments); ‘in vitro’;
‘in silico’; ‘non-invasive animal research’ (e.g.
observational studies with wild animals); and ‘other human
studies’ (e.g. on social perceptions). The term ‘human
research’ referred to any human-based research that might
involve, among other things, the analysis of biological sam-
ples, epidemiological and behavioural studies, medical
case studies and clinical studies. A citing paper could be
allocated to more than one category, if it described different
research approaches. Whenever the category of the citing
paper could not be defined (due to language barriers or
absence of an abstract), the paper was labelled as ‘not
available’ and removed from further analysis.
Among the categories ‘human research’, ‘in silico’,
‘in vitro’ and ‘invasive animal research’, it was also
recorded whether the citing paper focused on MDD or
on other subjects.
Statistical analysis: To test for differences between the num-
bers of citations across research approaches, three general-
ised linear models (GLMs), each with a Poisson response
and a log link function, were implemented. Each model
tested one of the following response variables: (a) the total
number of citations; (b) the total number of citations by
papers in the category ‘human research’; and (c) the total
number of citations by papers in the category of ‘human
research’ that focused specifically on MDD. In each model,
the only explanatory variable was the type of research
approach, of which there were three: NHP studies, in
silico-based approaches and in vitro-based approaches. The
GLM’s goodness of fit was evaluated by visual inspection
of the diagnostic plots. Additionally, a Gaussian GLM was
used to evaluate whether the proportions of citations by
human research papers, and by human research papers spe-
cifically on MDD, were different across the three
approaches. The analyses were performed in R 3.6.1,33
by using the function glm. The results were considered
significant when p < 0.05.
Systematic qualitative analysis of citations
Citing papers featuring human research specifically on
MDD were systematically analysed by two independent
raters, to qualitatively evaluate the contribution of knowl-
edge from NHP studies, or from in vitro-based or in silico-
based research approaches, to the respective human
clinical study. Each study was rated according to the fol-
lowing classes, which were defined prospectively, as in
Carvalho et al.30:
– Redundant: when the cited study was only men-
tioned among other studies as an example. In the
case where multiple studies were used as examples
of one or more points, the raters were instructed to
rate the study as redundant only if there were older
or human studies stating exactly the same points.
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– Minor relevance: when the cited study was cited in
either the Discussion or the Introduction, to pro-
vide information not directly related to the hypoth-
esis explored in the human study.
– Relevant to the hypothesis: when the cited study was
cited in the Introduction, to provide information
relevant to the hypothesis explored in the human
study.
– Relevant to the methods: when the human study
used the same methodology as that described in
the cited paper, with the exception of species dif-
ferences in the case of NHP study methods.
A paper considered to be ‘relevant’ could be both relevant
for the hypothesis and the methods. The other options in the
classes are mutually exclusive. In all cases, disagreement
between the raters was resolved via detailed discussions
until a consensus was reached.
Whenever it was not possible to assess the contribution
of a cited paper to a human study due to unavailability of
the full publication on the human study, the human research
paper was labelled as ‘not available’ and removed from
further analysis.
A statistical test was used for comparing proportions
(Pearson’s 2 test implemented via R’s prop.test function),
in order to assess differences between the three cited
approaches (i.e. NHP studies, and in vitro-based and in
silico-based approaches). Since, even for the pair with the
largest difference, the null hypothesis of equal proportions
could not be rejected under the usual significance levels,
corrections for multiple comparisons were not attempted.
Results
Citation analysis
NHP study-based results: Nineteen publications featuring
NHP studies in the field of MDD research were retrieved,
which were subsequently cited 841 times in total. Of these
19 papers, five featured both human and NHP data.
The subsequent citing papers belonged to the following
categories: invasive animal research (312); reviews (245);
human research (152); in vitro research (81); in silico
research (14); non-invasive animal research (6); and opi-
nions, including editorials, comments or replies to com-
ments (4). Eighty-five citing papers were not categorised
due to being unavailable or written in a language other than
English, Portuguese or Italian.
Of the 312 citations by animal research papers, 63
were specifically focused on MDD; of the 152 citations
by human research papers, 71 were specifically focused
on MDD.
In silico-based approach results: Twenty-nine publications
describing the use of in silico-based approaches in the con-
text of MDD research were retrieved, which were
subsequently cited 806 times in total. Of these 29 papers,
seven featured both patient data and computer simulations.
The subsequent citing papers belonged to the following
categories: human research (317); in silico research (193);
reviews (193); invasive animal research (44); in vitro
research (17); and opinions (17). Fifty-eight citing papers
were not categorised due to being unavailable or written in
a language other than English, Portuguese or Italian.
Of the 317 citations by human research papers, 94 spe-
cifically focused on MDD; of the 193 citations by in silico-
based research papers, 36 specifically focused on MDD.
In vitro-based approach results: Thirty-eight publications
describing the use of in vitro-based approaches in the
context of MDD research were retrieved, which were sub-
sequently cited 2,574 times in total. All of the in vitro-
based papers used samples of human biological material,
mostly being obtained from MDD patients (in 34 out of
the 38 studies).
The subsequent citing papers belonged to the following
categories: in vitro research (1,239), resorting to the use of
human biological material (789), laboratory animal biolo-
gical material (373) or biological material from both
sources (12); human research (978), of which 189 studies
solely used human participants without concurrent use of in
vitro-based research approaches; reviews (844); invasive
animal research (464), of which 79 studies solely used live
animals without concurrent use of in vitro-based research
approaches; opinions (27); and in silico research (16). One
hundred and fifty-four citing papers were not categorised
due to being unavailable or written in a language other than
English, Portuguese or Italian.
Of the 978 citations by human research papers, 482
specifically focused on MDD; of the 1,239 citations by in
vitro research papers, 487 specifically focused on MDD.
Comparison of citations of papers based on NHP
studies, in vitro approaches and in silico approaches
An inspection of the diagnostic plots showed no reason for
concern with regard to the GLM fit. Among the papers
using an in vitro-based approach, one was frequently cited
(711 citations). We performed the analysis both with and
without this potential outlier and found no significant dif-
ferences between the two scenarios.
The GLM estimated the average number of citations per
paper for each of the three approaches (Figure 1 (a)). Each
NHP paper was cited 3.73 times (standard error (SE): 0.03).
Papers based on in silico approaches were cited less fre-
quently than this (3.29 times; i.e. 0.44, SE: 0.05), and
papers based on in vitro approaches were cited more fre-
quently (4.23 times; i.e. þ0.5, SE: 0.04). Both differences
were statistically significant (p < 0.0001).
With regard to the average number of subsequent cita-
tions by human research papers (Figure 1 (b)), each NHP
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paper was cited 2.03 times (SE: 0.08). In comparison,
papers based on in vitro and in silico approaches were more
frequently cited (þ1.09, SE: 0.09 and þ0.33, SE: 0.10,
respectively). These differences were statistically signifi-
cant (p < 0.001).
When looking at the average numbers of citations by
human research papers specifically focused on MDD (Fig-
ure 1 (c)), each NHP paper was cited 1.27 times (SE: 0.12),
which was not statistically different from the number of
citations of papers based on in silico approaches (0.12,
SE: 0.16). In these MDD-specific publications, papers
based on in vitro approaches received, on average, more
citations (þ1.3, SE: 0.13) than papers based on NHP
studies, and the difference was statistically significant
(p < 0.001).
The estimated proportion of citations of NHP papers by
human research papers was 0.13 (SE: 0.05). This propor-
tion was significantly higher for papers based on in silico
approaches (þ0.20, SE: 0.07, p ¼ 0.004) and also for
papers based on in vitro approaches (þ0.30, SE: 0.07,
p < 0.0001).
The estimated proportion of citations of NHP papers by
human research papers specifically focused on MDD was
0.06 (SE: 0.03), which was not significantly different from
the proportion of citations of papers based on in silico
approaches (þ0.06, SE: 0.04, p ¼ 0.1389). The proportion
of citations in these MDD-specific publications, of papers
based on in vitro approaches (þ0.14, SE: 0.04), was
significantly different from that of the NHP papers
(p ¼ 0.001).
Systematic qualitative analysis of citations
Of the 71 human research papers specifically focused on
MDD that cited NHP papers, 50 (70%) were fully available
for further analysis, along with 401 of the 482 (83%)
Figure 1. The number of citations received by the retrieved papers, according to research approach. A bibliographic search was
carried out to retrieve papers on MDD, which were categorised as based on NHP studies or in silico or in vitro approaches, according to
the research method described. A citation analysis was then performed to identify papers that subsequently cited these retrieved
papers. The graphs show: (a) the total number of times that the retrieved papers were cited, according to their research approach;
(b) the number of times that the retrieved papers were cited by papers on human research, according to their research approach; and
(c) the number of times that the retrieved papers were cited by papers on human research specifically focused on MDD, according to
their research approach. For visualisation purposes, the largest observation in the ‘In vitro’ category was excluded from the data used to
generate the graphs. MDD: major depressive disorder; NHP: non-human primate.
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human research papers on MDD that cited in vitro-based
papers, and 58 of the 94 (62%) human research papers on
MDD that cited in silico-based papers. It was judged that
eight of 50 (16%), 15 of 58 (25%) and 100 of 401 (25%) of
citations of papers based on NHP studies, in silico and in
vitro approaches, respectively, were relevant to the hypoth-
esis and/or the methods in the citing human research paper
on MDD (see Table 1).
The statistical test used to compare the proportions did not
reveal any significant differences between the proportions of
relevant citations between NHP–in vitro, NHP–in silico and
in vitro–in silico (p ¼ 0.31, 0.20 and 1, respectively).
Discussion
We quantitatively and qualitatively analysed the contribu-
tion of NHP, in vitro and in silico-based research
approaches to the contemporary understanding of MDD.
Of the three approaches analysed, NHP studies seemed to
be the approach that was least likely to contribute to
furthering progress in this field of human medical research.
Of the three, the human-based in vitro approach seemed to
influence human research to the greatest extent, judging
by the number of citations. However, all three approaches
seemed to be equally relevant in informing the hypothesis
and/or methods of subsequent human research studies.
Overall, our results suggest that these less funded non-
animal research approaches34 are more or equally effective
than heavily invested animal-based research in reaching
their final goal — which is to inform clinical research to
improve human healthcare. Our quantitative results showed
that in silico-based and in vitro-based approaches contrib-
uted more than NHP study-based approaches to human
medical research, as the proportion of cited papers featur-
ing the former two approaches was higher than the propor-
tion of cited papers featuring the latter. NHP study-based
papers were mainly cited by other papers on animal experi-
mentation, which suggests that they are mainly contribut-
ing to subsequent animal research rather than to advances
in human healthcare. In vitro studies seemed to be the most
effective approach, since this approach received signifi-
cantly more citations in total, and by human research
papers either specifically focused on MDD or on other
general medical areas.
Of the five analysed NHP study-based papers that were
relevant to the citing human research papers on MDD in
terms of their hypothesis, method or both, one featured both
NHP and human research data. This paper was cited twice,
and both citing papers referred to the human research data
rather than to the NHP data. Another one of these five NHP
papers was considered relevant to the methods and was
cited once. The citing paper described both human and
rhesus monkey data, and the citation was relevant to the
methods used with the rhesus monkeys. After excluding
these cases, only three out of the 19 NHP studies were
relevant to the hypothesis and/or methods of the subsequent
human research studies on MDD.
The results of our citation analysis also suggest that the
widely accepted approach to testing medical hypotheses —
which relies on in vitro-based and in silico-based research
as a preliminary step prior to animal testing — is not actu-
ally working as intended, since clinical papers tend to cite
in silico-based and in vitro-based papers directly too. How-
ever, citations of in silico-based and in vitro-based papers
in subsequent publications on human clinical studies of
MDD constituted a low percentage (50% or less) of the
total citations received in all three analysed categories. This
may be explained by the complexity of MDD, which shares
certain genetic factors, phenotypic traits and possible neu-
rologic pathways with a number of other disorders. Hence,
a human study on anorexia might cite a non-clinical study
on MDD focused on weight loss, since weight change is
one of the symptoms of MDD.
As to the qualitative results, the judged relevance of the
initially retrieved papers to the publications subsequently
citing them was low for all three analysed research
approaches. Even though a higher percentage of cited in
silico-based and in vitro-based papers were relevant to the
hypothesis and/or methods used by the citing clinical
studies, the differences between the three approaches, in
the extent of their judged relevance, were deemed insig-
nificant. However, the size of the observed effect —
where the proportion of citations of NHP-based papers
was much lower than that of in silico-based or in vitro-
based papers — suggests that, while not statistically
Table 1. The relevance of cited NHP study-based, in silico-based or in vitro-based papers to subsequent (i.e. citing) human research
papers focused on MDD.a
Citations which are:
Papers based
on NHP studies
Papers based
on in silico approaches
Papers based
on in vitro approaches Total
Redundant or of minor relevance 42 (84%) 43 (75%) 301 (75%) 386
Relevant to the hypothesis or to the methods 8 (16%) 15 (25%) 100 (25%) 123
Total 50 58 401 509
MDD: major depressive disorder; NHP: non-human primate.
aThe relevance or redundancy of the cited paper to the hypothesis or methods of the citing MDD paper was evaluated by two independent raters.
Bold: total value.
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significant (due to lack of statistical power), there might
be a relevant practical difference.
Several important developments in in vitro technologies
(e.g. organs-on-chips35) and in in silico technologies (e.g.
advanced artificial intelligence based on sophisticated
machine learning tools36) have been published since
2011. Such studies have been excluded from our analysis,
in order to ensure that sufficient time is given to allow for
subsequent citation of the resulting papers. However, it is
reasonable to expect that these cutting-edge technologies
are currently being widely used to generate and test new
hypotheses in human medicine.27 Similarly, induced plur-
ipotent stem cells, even though they have been worked on
and developed for more than a decade,37 have only recently
been recommended for MDD research.38 In light of the
above, it would be interesting to repeat the current study
a decade from now to investigate whether this has led to an
increase in the number of subsequent citations of in vitro-
based and in silico-based papers on MDD, in both MDD-
focused and general human research publications.
We recognise that our study has certain limitations.
Due to resource constraints, we were unable to use a
greater number of search engines (e.g. CAB Abstracts).
This would have increased the likelihood of retrieving
all in silico-based, in vitro-based and NHP study-based
papers on MDD, which would have increased our sam-
ple size and thus made it more comprehensive. Simi-
larly, we were unable to examine the reference lists of
many of the retrieved papers, in order to locate addi-
tional relevant papers. This inevitably means that some
relevant publications might not have been identified.
Because the sample size was small, our results should
be interpreted with this caveat.
Finally, we are aware of the difficulty in objectively
determining the relevance of a cited paper to the publica-
tion citing it. We used two different raters, in order to
attempt to decrease any error in subjective assessment.
Occasionally, the raters differed in their initial assessment,
indicating that, even when the same criteria are used for
assessment, differences can sometimes arise. However, our
experience suggests that these differences would relate to
only a small proportion of the papers assessed. Despite the
limitations in the citation search and in the systematic qua-
litative analysis of the citation value, we consider that the
method we followed is useful when evaluating the effec-
tiveness of different research approaches. We hope that
similar studies adopt this methodology, in order to investi-
gate other medical disorders.
Our results suggest that the contribution of NHP studies
to the current understanding of MDD is poor, and that other
approaches with potentially superior relevance to humans
should be used. Our results also shed light on the contro-
versy around the efficacy of NHP-based research for
investigating human disorders. This controversy is long-
standing, with some authors claiming that their use is
crucial for medical advancement,23 while others assert the
opposite.39,40 However, ongoing scientific advances in
non-animal methods for the acquisition of knowledge and
the development of new treatments may provide future
alternative solutions to help avoid the dilemmas and con-
cerns surrounding NHP use.
Conclusions
To our knowledge, this is the first study to compare the
effectiveness of original studies involving the use of NHP,
in vitro and in silico research approaches to inform the
medical research community within the MDD field. Our
results suggest that, in this field of medical research,
human-based in vitro and in silico research approaches are
more promising than NHP studies, in generating new
hypotheses and methods for subsequent clinical research.
Given the scientific advances in human-based research
methods, we suggest that our methodology could be used in
the future to analyse the impact of more recent technologies
in informing human medical research. Such analysis could
examine if and how the standard paradigm for testing med-
ical hypotheses is still being followed, from applied
research, through animal use in preclinical testing, and on
to clinical research and development. It could also provide
further insight into how the ‘gold standard’ that considers
in vitro-based and in silico-based research approaches as
merely preliminary steps prior to animal testing could be
challenged and revised. Given the scientific and ethical
solutions that innovative human-based approaches are pro-
viding, with relatively little investment when compared to
the investments in animal-based research, a reallocation of
resources is clearly warranted in favour of researching and
developing the use of such approaches as part of human
medical research.
Acknowledgements
The authors would like to acknowledge the University of Lisbon
EcoComp team members for their valuable insights during the
conception and design of this study.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship and/or publication of this
article.
Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship and/or publication of this article: This
study was financed by Animalfree Research–Switzerland, and by
Portuguese national funds through FCT–Fundac¸a˜o para a Cieˆncia
e a Tecnologia, within the CFCUL Unit funding UID/FIL/00678/
2013. TAM received partial support from CEAUL (funded by
FCT–Fundac¸a˜o para a Cieˆncia e a Tecnologia, Portugal, through
the project UID/MAT/00006/2019). Open access publication
costs were covered by Animalfree Research–Switzerland and by
134 Alternatives to Laboratory Animals 47(3-4)
funding provided by the Ketty and Leif Hjordt Foundation. None
of these funders played any role in the study conceptualisation,
design, conduct, data collection or analysis, authorship of the
resulting manuscript or the decision to submit it for publication.
Ethical approval
Ethics approval was not required for this article.
Informed consent
Informed consent was not required for this article.
References
1. WHO. Depression, key facts. Geneva: World Health Organi-
zation, https://www.who.int/news-room/fact-sheets/detail/
depression (2018, accessed 29 June 2019).
2. Cuijpers P, Vogelzangs N, Twisk J, et al. Comprehensive
meta-analysis of excess mortality in depression in the general
community versus patients with specific illnesses. Am J Psy-
chiatry 2014; 171: 453–462.
3. Li CT, Bai YM, Tu PC, et al. Major depressive disorder and
stroke risks: a 9-year follow-up population-based, matched
cohort study. PLoS One 2012; 7: e46818.
4. Rauma PH, Pasco JA, Berk M, et al. The association between
major depressive disorder, use of antidepressants and bone
mineral density (BMD) in men. J Musculoskelet Neuronal
Interact 2015; 15: 177–185.
5. American Psychiatric Association. DSM-5: Manual diagno´s-
tico e estatı´stico de transtornos mentais. Sa˜o Paulo: Artmed
Editora, 2014, p. 992.
6. Vos T, Allen C, Arora M, et al. Global, regional, and national
incidence, prevalence, and years lived with disability for 310
diseases and injuries, 1990–2015: a systematic analysis for
the Global Burden of Disease Study 2015. Lancet 2016; 388:
1545–1602.
7. Sobocki P, Jonsson B, Angst J, et al. Cost of depression in
Europe. J Ment Health Policy Econ 2006; 9: 87–98.
8. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of
mental disorders and other disorders of the brain in Europe
2010. Eur Neuropsychopharmacol 2011; 21: 655–679.
9. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic
burden of adults with major depressive disorder in the United
States (2005 and 2010). J Clin Psychiatry 2015; 76: 155–162.
10. Maurer K and Quimby F. Animal models in biomedical
research. In: Fox JG, Anderson LC, Otto GM, Pritchett-Corn-
ing KR and Whary MT (eds) Laboratory animal medicine.
4th ed. Cambridge: Academic Press, 2015, pp. 1497–1534.
11. Anon. Special Eurobarometer 340/Wave 73.1: science and
technology. Report, European Commission, Brussels, June
2010, http://ec.europa.eu/commfrontoffice/publicopinion/
archives/ebs/ebs_340_en.pdf (accessed 29 June 2019).
12. Lankau EW, Turner PV, Mullan RJ, et al. Use of nonhuman
primates in research in North America. J Am Assoc Lab Anim
Sci 2014; 53: 278–282.
13. Anon. Animal Welfare Act 1999. Wellington: New Zealand
Government, http://www.legislation.govt.nz/act/public/1999/
0142/59.0/DLM49664.html (1999, accessed 19 August 2019).
14. Kraskov A, Prabhu G, Quallo MM, et al. Ventral premotor–
motor cortex interactions in the macaque monkey during
grasp: response of single neurons to intracortical microstimu-
lation. J Neurosci 2011; 31: 8812–8821.
15. Vigneswaran G, Philipp R, Lemon RN, et al. M1 corticosp-
inal mirror neurons and their role in movement suppression
during action observation. Curr Biol 2013; 23: 236–243.
16. Maninger N, Capitanio JP, Mason WA, et al. Acute and
chronic stress increase DHEAS concentrations in rhesus
monkeys. Psychoneuroendocrinology 2010; 35: 1055–1062.
17. Knight A. Laboratory animal statistics for Great Britain:
implications for animal welfare. AATEX 2010; 17: 51–52.
18. Gottlieb DH, Capitanio JP and McCowan B. Risk factors for
stereotypic behavior and self-biting in rhesus macaques
(Macaca mulatta): animal’s history, current environment,
and personality. Am J Primatol 2013; 75: 995–1008.
19. Morgan KN and Tromborg CT. Sources of stress in captivity.
Appl Anim Behav Sci 2007; 102: 262–302.
20. Buller T. Animal minds and neuroimaging: bridging the gap
between science and ethics? Camb Q of Healthc Ethics 2014;
23: 173–181.
21. Keen J. Wasted money in United States biomedical and agri-
cultural animal research. In: Herrmann K and Jayne K (eds)
Animal experimentation: working towards a paradigm
change. Leiden: Brill, 2019, pp. 244–272.
22. Fitzgerald TA. Comparison of research cost: man–primate ani-
mal–other animal models. J Med Primatol 1982; 12: 138–145.
23. Worlein JM. Nonhuman primate models of depression:
effects of early experience and stress. ILAR J 2014; 55:
259–273.
24. Pound P and Bracken MB. Is animal research sufficiently
evidence based to be a cornerstone of biomedical research?
BMJ 2014; 348: g3387.
25. Carvalho C, Alves D, Knight A, et al. Is animal-based
biomedical research being used in its original context?
In: Herrmann K and Jayne K (eds) Animal experimenta-
tion: working towards a paradigm change. Leiden: Brill,
2019, pp. 376–390.
26. Benam KH, Gilchrist S, Kleensang A, et al. Exploring new
technologies in biomedical research. Drug Discov Today
2019; 24: 1242–1247.
27. Archibald K, Tsaioun K, Kenna JG, et al. Better science for
safer medicines: the human imperative. J R Soc Med 2018;
111: 433–438.
28. Taylor K. Recent developments in alternatives to animal test-
ing. In: Herrmann K and Jayne K (eds) Animal experimenta-
tion: working towards a paradigm change. Leiden: Brill,
2019, pp. 583–609.
29. Langley GR, Adcock IM, Busquet F, et al. Towards a 21st-
century roadmap for biomedical research and drug discovery:
consensus report and recommendations. Drug Discov Today
2017; 22: 327–339.
Carvalho et al. 135
30. Carvalho C, Crespo MV, Bastos LF, et al. Contribution of
animal models to contemporary understanding of atten-
tion deficit hyperactivity disorder. ALTEX 2016; 33:
243–249.
31. Uman L. Systematic reviews and meta-analyses. J Can Acad
Child Adolesc Psychiatry 2011; 20: 57–59.
32. Wooding S, Pollitt A, Castle-Clarke S, et al. Mental Health
Retrosight: Understanding the returns from research (lessons
from schizophrenia): policy report. Rand Health Q 2014;
4(1): 8.
33. R Core Team. R: a language and environment for statistical
computing. Vienna: R Foundation for Statistical Computing,
https://www.R-project.org (2018, accessed 21 August
2019).
34. Frank J. Technological lock-in, positive institutional feed-
back, and research on laboratory animals. Struct Change
Econ D 2005; 16: 557–575.
35. Bhatia SN and Ingber DE. Microfluidic organs-on-chips.
Nature Biotech 2014; 32: 760–772.
36. Batool M, Ahmad B and Choi S. A structure-based drug
discovery paradigm. Int J Mol Sci 2019; 20: 2783.
37. Romito A and Cobellis G. Pluripotent stem cells: current
understanding and future directions. Stem Cells Int 2016;
2016: 9451492.
38. Licinio J and Wong ML. Serotonergic neurons derived from
induced pluripotent stem cells (iPSCs): a new pathway for
research on the biology and pharmacology of major depres-
sion. Mol Psychiatry 2016; 21: 1–2.
39. Knight A. The poor contribution of chimpanzee experiments
to biomedical progress. J Appl Anim Welf Sci 2007; 10:
281–308.
40. Bailey J and Taylor K. Non-human primates in neuroscience
research: the case against its scientific necessity. Altern Lab
Anim 2016; 44: 43–69.
Appendix 1: A list of retrieved articles
In vitro-based approach
Bartlett JA, Demetrikopoulos MK, Schleifer SJ, et al. Phagocytosis and killing of Staphylococcus aureus: effects of
stress and depression in children. Clin Diagn Lab Immunol 1997; 4: 362–366.
Bertilsson L, Aberg-Wistedt A, Lide´n A, et al. Alprazolam does not inhibit the metabolism of nortriptyline in depressed
patients or inhibit the metabolism of desipramine in human liver microsomes. Ther Drug Monit 1988; 10: 231–233.
Brusov OS, Beliaev BS, Katasonov AB, et al. Development of subsensitivity to imipramine in the system of reverse
serotonin uptake by thrombocytes in patients with endogenous depression. Zh Nevropatol Psikhiatr Im S S Korsakova
1988; 88: 96–100.
Chen B, Dowlatshahi D, MacQueen GM, et al. Increased hippocampal BDNF immunoreactivity in subjects treated
with antidepressant medication. Biol Psychiatry 2001; 50: 260–265.
Conklin SM, Runyan CA, Leonard S, et al. Age-related changes of n-3 and n-6 polyunsaturated fatty acids in the
anterior cingulate cortex of individuals with major depressive disorder. Prostaglandins Leukot Essent Fatty Acids 2010;
82: 111–119.
De Paermentier F, Cheetham SC, Crompton MR, et al. Lower cortical beta-adrenoceptor binding sites in post-mortem
samples from depressed suicide victims. Br J Pharmacol 1989; 98: 818P.
Du L, Faludi G, Palkovits M, et al. Frequency of long allele in serotonin transporter gene is increased in depressed
suicide victims. Biol Psychiatry 1999; 46: 196–201.
Ebstein RP, Lerer B, Shapira B, et al. Cyclic AMP second-messenger signal amplification in depression. Br J
Psychiatry 1988; 152: 665–669.
Franke L, Schewe HJ, Uebelhack R, et al. Platelet-5HT uptake and gastrointestinal symptoms in patients
suffering from major depression. Life Sci 2003; 74: 521–531.
Garbin L, Bianchin GL, De Bertolini C, et al. Inhibitory effect of imipramine on epinephrine-dependent platelet
aggregation: “in vitro” studies on platelets from healthy and depressed people. Pharmacol Res Commun 1983; 15:
23–27.
Gilad GM, Gilad VH, Casanova MF, et al. Polyamines and their metabolizing enzymes in human frontal cortex and
hippocampus: preliminary measurements in affective disorders. Biol Psychiatry 1995; 38: 227–234.
Greenstein AS, Paranthaman R, Burns A, et al. Cerebrovascular damage in late-life depression is associated with
structural and functional abnormalities of subcutaneous small arteries. Hypertension 2010; 56: 734–740.
Heiser P, Lanquillon S, Krieg JC, et al. Differential modulation of cytokine production in major depressive disorder by
cortisol and dexamethasone. Eur Neuropsychopharmacol 2008; 18: 860–870.
Himmerich H, Fulda S, Sheldrick AJ, et al. IFN-g reduction by tricyclic antidepressants. Int J Psychiatry Med 2010; 40:
413–424.
Hing B, Davidson S, Lear M, et al. A polymorphism associated with depressive disorders differentially regulates brain
derived neurotrophic factor promoter IV activity. Biol Psychiatry 2012; 71: 618–626.
136 Alternatives to Laboratory Animals 47(3-4)
Hrdina PD, Demeter E, Vu TB, et al. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide
victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res 1993; 614: 37–44.
Irwin M, Costlow C, Williams H, et al. Cellular immunity to varicella-zoster virus in patients with major depression. J
Infect Dis 1998; 178: S104–S108.
Karege F, Bovier P, Widmer J, et al. Decrease in epinephrine-induced attenuation of platelet adenylate cyclase activity
in depressed patients: relation with plasma electrolytes. Neuropsychobiology 1992; 26: 129–135.
Kim YK, Lee SW, Kim SH, et al. Differences in cytokines between non-suicidal patients and suicidal patients in major
depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 356–361.
Klimek V, Roberson G, Stockmeier CA et al. Serotonin transporter and MAO-B levels in monoamine nuclei of the
human brainstem are normal in major depression. J Psychiatr Res 2003; 37: 387–397.
Kok FW, Heijnen CJ, Bruijn JA, et al. Immunoglobulin production in vitro in major depression: a pilot study on the
modulating action of endogenous cortisol. Biol Psychiatry 1995; 38: 217–226.
Kubera M, Kenis G, Bosmans E, et al. Stimulatory effect of antidepressants on the production of IL-6. Int Immuno-
pharmacol 2004; 4: 185–192.
Lawrence KM, De Paermentier F, Cheetham SC, et al. Brain 5-HT uptake sites, labelled with [3H]-paroxetine, in post-
mortem samples from depressed suicide victims. Br J Pharmacol 1989; 98: 812P.
Lawrence KM, Falkowski J, Jacobson RR, et al. Platelet 5-HT uptake sites in depression: three concurrent measures
using [3H] imipramine and [3H] paroxetine. Psychopharmacol 1993; 110: 235–239.
Lin A, Song C, Kenis G, et al. The in vitro immunosuppressive effects of moclobemide in healthy volunteers. J Affect
Disord 2000; 58: 69–74.
Maes M and Thompson P. Analysis of partial variance to control for day-to-day variability in functional immune tests
in depression. Neuropsychobiology 1997; 36: 107–111.
Mann JJ, Brown RP, Halper JP, et al. Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with
endogenous depression and psychomotor agitation. N Eng J Med 1985; 313: 715–720.
Miguel-Hidalgo JJ, Baucom C, Dilley G, et al. Glial fibrillary acidic protein immunoreactivity in the prefrontal
cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 2000; 48: 861–873.
Mikuni M, Kusumi I, Kagaya A, et al. Increased 5-HT-2 receptor function as measured by serotonin-stimulated
phosphoinositide hydrolysis in platelets of depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 1991; 15:
49–61.
Miller GE, Rohleder N, Stetler C, et al. Clinical depression and regulation of the inflammatory response during acute
stress. Psychosom Med 2005; 67: 679–687.
Mizrahi C, Stojanovic A, Urbina M, et al. Differential cAMP levels and serotonin effects in blood peripheral mono-
nuclear cells and lymphocytes from major depression patients. Int Immunopharmacol 2004; 4: 1125–1133.
Molnar M, Potkin SG, Bunney WE, et al. MRNA expression patterns and distribution of white matter neurons in
dorsolateral prefrontal cortex of depressed patients differ from those in schizophrenia patients. Biol Psychiatry 2003; 53:
39–47.
Morishita S, Aoki S and Watanabe S. Different effect of desipramine on protein kinase C in platelets between bipolar
and major depressive disorders. Psychiatry Clin Neurosci 1999; 53: 11–15.
Perry EK, Marshall EF, Blessed G, et al. Decreased imipramine binding in the brains of patients with depressive illness.
Br J Psychiatry 1983; 142: 188–192.
Szentistvanyi I, Janka Z and Rimanoczy A. Alteration of erythrocyte phosphate transport in primary depressive
disorders. J Affect Disord 1980; 2: 229–238.
Valdiza´n EM, Gutierrez O and Pazos A. Adenylate cyclase activity in postmortem brain of suicide subjects: reduced
response to -adrenergic stimulation. Biol Psychiatry 2003; 54: 1457–1464.
Wood PL, Suranyi-Cadotte BE, Nair NPV, et al. Lack of association between [3H]imipramine binding sites and uptake
of serotonin in control, depressed and schizophrenic patients. Neuropharmacol 1983; 22: 1211–1214.
In silico-based approach
Becker S, MacQueen G and Wojtowicz JM. Computational modeling and empirical studies of hippocampal
neurogenesis-dependent memory: effects of interference, stress and depression. Brain Res 2009; 1299: 45–54.
Bulmash EL, Moller HJ, Kayumov L, et al. Psychomotor disturbance in depression: assessment using a driving
simulator paradigm. J Affect Disord 2006; 93: 213–218.
Bursi R, Erdemli G, Campbell R, et al. Translational PK–PD modelling of molecular target modulation for the AMPA
receptor positive allosteric modulator Org 26576. Psychopharmacol 2011; 218: 713–724.
Carvalho et al. 137
Costafreda SG. Parametric coordinate-based meta-analysis: valid effect size meta-analysis of studies with differing
statistical thresholds. J Neurosci Methods 2012; 210: 291–300.
Demirtas H and Doganay B. Simultaneous generation of binary and normal data with specified marginal and associ-
ation structures. J Biopharm Stat 2012; 22: 223–236.
Fischer K, Goetghebeur E, Vrijens B, et al. A structural mean model to allow for noncompliance in a randomized trial
comparing 2 active treatments. Biostatistics 2010; 12: 247–257.
Gardner W, Shear K, Kelleher KJ, et al. Computerized adaptive measurement of depression: a simulation study. BMC
Psychiatry 2004; 4: 13.
Giuffra LA and Risch N. Diminished recall and the cohort effect of major depression: a simulation study. Psychol Med
1994; 24: 375–383.
Heo M and Leon AC. Sample sizes required to detect two-way and three-way interactions involving slope differences
in mixed-effects linear models. J Biopharm Stat 2010; 20: 787–802.
Hida E and Tango T. On the three-arm non-inferiority trial including a placebo with a prespecified margin. Stat Med
2010; 30: 224–231.
Javaras KN, Hudson JI and Laird NM. Fitting ACE structural equation models to case-control family data. Genet
Epidemiol 2009; 34: 238–245.
Koshelev M, Lohrenz T, Vannucci M, et al. Biosensor approach to psychopathology classification. PLoS Comput Biol
2010; 6: e1000966.
Merlo-Pich E, Alexander RC, Fava M, et al. A new population-enrichment strategy to improve efficiency of placebo-
controlled clinical trials of antidepressant drugs. Clin Pharmacol Ther 2010; 88: 634–642.
Partonen T, Treutlein J, Alpman A, et al. Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter
depression. Ann Med 2007; 39: 229–238.
Patten SB. An animated depiction of major depression epidemiology. BMC Psychiatry 2007; 7: 23.
Patten SB. The National Population Health Survey’s assessment of depression risk factor associations: a simulation
study assessing vulnerability to bias. Chronic Dis Inj Can 2012; 32: 70–75.
Santen G, Horrigan J, Danhof M, et al. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in
the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther 2009; 86: 255–262.
Serretti A, Olgiati P, Bajo E, et al. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of
major depressive disorders. World J Biol Psychiatry 2011; 12: 501–515.
Shang EY, Gibbs MA, Landen JW, et al. Evaluation of structural models to describe the effect of placebo upon the time
course of major depressive disorder. J Pharmacokinet Pharmacodyn 2009; 36: 63–80.
Shen J, Moller HJ, Wang X, et al. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with
major depressive disorder: a prospective, randomized trial of 28 patients. J Clin Psychiatry 2009; 70: 370–377.
Shults J, Sun W, Tu X, et al. A comparison of several approaches for choosing between working correlation structures
in generalized estimating equation analysis of longitudinal binary data. Stat Med 2009; 28: 2338–2355.
Slade T. Taxometric investigation of depression: evidence of consistent latent structure across clinical and community
samples. Aust N Z J Psychiatry 2007; 41: 403–410.
Soeteman DI, Miller M and Kim JJ. Modeling the risks and benefits of depression treatment for children and young
adults. Value Health 2012; 15: 724–729.
Suckling J and Bullmore E. Permutation tests for factorially designed neuroimaging experiments. Human Brain Mapp
2004; 22: 193–205.
Taub NA, Morgan Z, Brugha TS, et al. Recalibration methods to enhance information on prevalence rates from large
mental health surveys. Int J Methods Psychiatr Res 2005; 14: 3–13.
Tretter F, Gebicke-Haerter PJ, An Der Heiden U, et al. Affective disorders as complex dynamic diseases — a
perspective from systems biology. Pharmacopsychiatry 2011; 44: S2–S8.
Wang X, Lin Y, Song C, et al. Detecting disease-associated genes with confounding variable adjustment and the
impact on genomic meta-analysis: with application to major depressive disorder. BMC Bioinformatics 2012; 13: 52.
Weigelt K, Carvalho LA, Drexhage RC, et al. TREM-1 and DAP12 expression in monocytes of patients with severe
psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. Brain Behav Immun 2011; 25: 1162–
1169.
Zhang WR, Pandurangi AK and Peace KE. YinYang dynamic neurobiological modeling and diagnostic analysis of
major depressive and bipolar disorders. IEEE Trans Biomed Eng 2007; 54: 1729–1739.
Zubenko GS and Hughes HB. Effects of the G(-656)A variant on CREB1 promoter activity in a glial cell line:
interactions with gonadal steroids and stress. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 579–585.
138 Alternatives to Laboratory Animals 47(3-4)
Non-human primate study-based
Eggan SM, Stoyak SR, Verrico CD, et al. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex:
comparison of schizophrenia and major depressive disorder. Neuropsychopharmacol 2010; 35: 2060–2071.
Feyissa AM, Woolverton WL, Miguel-Hidalgo JJ, et al. Elevated level of metabotropic glutamate receptor 2/3 in the
prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 279–283.
Freedman LJ, Insel TR and Smith Y. Subcortical projections of area 25 (subgenual cortex) of the macaque monkey. J
Comp Neurol 2000; 421: 172–188.
Fuchs E, Cze´h B, Michaelis T, et al. Synaptic plasticity and tianeptine: structural regulation. Eur Psychiatry 2002;
17(Suppl 3): 311–317.
Goncharova ND, Marenin VY and Oganyan TE. Aging of the hypothalamic-pituitary-adrenal axis in nonhuman
primates with depression-like and aggressive behavior. Aging 2010; 2: 854–866.
Kraemer GW, Ebert MH, Lake CR, et al. Cerebrospinal fluid measures of neurotransmitter changes associated with
pharmacological alteration of the despair response to social separation in rhesus monkeys. Psychiatry Res 1984; 11:
303–315.
Kraemer GW and McKinney WT. Interactions of pharmacological agents which alter biogenic amine metabolism
and depression: an analysis of contributing factors within a primate model of depression. J Affect Disord 1979; 1:
33–54.
Lu NZ, Eshleman AJ, Janowsky A, et al. Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding,
distribution, and function in female macaques. Mol Psychiatry 2003; 8: 353–360.
Lyons DM, Wang OJ, Lindley SE, et al. Separation induced changes in squirrel monkey hypothalamic-pituitary-
adrenal physiology resemble aspects of hypercortisolism in humans. Psychoneuroendocrinology 1999; 24: 131–142.
Moscrip TD, Terrace HS, Sackeim HA, et al. A primate model of anterograde and retrograde amnesia produced by
convulsive treatment. J ECT 2004; 20: 26–36.
Nabulsi N, Huang Y, Weinzimmer D, et al. High-resolution imaging of brain 5-HT1B receptors in the rhesus
monkey using [11C]P943. Nucl Med Biol 2010; 37: 205–214.
Pickar D, Naber D, Post RM, et al. Measurement of endorphins in CSF. Relationship to psychiatric diagnosis. Mod
Probl Pharmacopsychiatry 1981; 17: 246–262.
Pongrac JL, Middleton FA, Peng L, et al. Heat shock protein 12A shows reduced expression in the prefrontal cortex of
subjects with schizophrenia. Biol Psychiatry 2004; 56: 943–950.
Qiao M, Zhao Q, Zhang H, et al. Isolating with physical restraint low status female monkeys during luteal phase might
make an appropriate premenstrual depression syndrome model. J Affect Disord 2007; 102: 81–91.
Rasmussen KL and ReiteM. Loss-induced depression in an adult macaquemonkey. Am J Psychiatry 1982; 139: 679–681.
Shively CA, Friedman DP, Gage HD, et al. Behavioral depression and positron emission tomography-determined
serotonin 1A receptor binding potential in cynomolgus monkeys. Arch Gen Psychiatry 2006; 63: 396–403.
Shively CA, Register TC, Adams MR, et al. Depressive behavior and coronary artery atherogenesis in adult
female cynomolgus monkeys. Psychosom Med 2008; 70: 637–645.
Spellman T, Peterchev AV and Lisanby SH. Focal electrically administered seizure therapy: a novel form of ECT
illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction. Neuropsychophar-
macol 2009; 34: 2002–2010.
Szewczyk B, Albert PR, Rogaeva A, et al. Decreased expression of Freud-1/CC2D1A, a transcriptional repressor of the 5-
HT1A receptor, in the prefrontal cortex of subjects withmajor depression. Int J Neuropsychopharmacol 2010; 13: 1089–1101.
Van Kampen M, Kramer M, Hiemke C, et al. The chronic psychosocial stress paradigm in male tree shrews: evaluation
of a novel animal model for depressive disorders. Stress 2002; 5: 37–46.
Carvalho et al. 139
